ClinicalTrials.gg
RecruitingNCT05879276EMPASHOCKUpdated Jun 27, 2025

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

A Phase 3 interventional study of Empagliflozin 10 MG in Cardiogenic Shock, sponsored by Central Hospital, Nancy, France. Recruiting at 8 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-27.

Sponsored by Central Hospital, Nancy, France · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Shock, Cardiogenic by Central Hospital, Nancy, France — 2 open to participants now, 3 under way, 1 of them phase 3. Shock, Cardiogenic · Central Hospital, Nancy, France.

Started
2024
the only one that year
Phase 3
2 of 12
1 open now
Registered
9th of 12
by date

Among the 12 studies in Shock, Cardiogenic by Central Hospital, Nancy, France, this one is the only one that started in 2024, is one of 2 in phase 3, and was the 9th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

2 of the 12 studies in Shock, Cardiogenic by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Shock, Cardiogenic by Central Hospital, Nancy, France, or all of them as a file.
02

Study summary

Long term prognosis of cardiogenic shock is related to the resolution of haemodynamic failure, associated visceral failure and the recovery of an adequate myocardial function. In the immediate aftermath of cardiogenic shock, after catecholamines weaning, there are no recommendations on cardiovascular treatments that would improve this long term prognosis. Indeed, the standard cardiovascular treatments such as inhibitors of the renin-angiotensin and aldosterone system and beta-blockers have hypotensive and negative inotropic effects and may worsen the renal function. In practice, given their side effects, they are not prescribed in the immediate aftermath of cardiogenic shock.

Sodium-glucose co-transporter 2 (iSGLT2) inhibitors are now an integral part of the drug management of chronic heart failure and the EMPULSE-HF trial has just demonstrated a benefit in acute heart failure (PMID: 35228754). Several pivotal clinical trials have demonstrated a significant effect of iSGLT2 on the survival and the risk of re hospitalisation for heart failure (PMID: 32865377, 31535829, 33200892). Our hypothesis is that, in patients in cardiogenic shock, early treatment with Empaglifozin in addition to the standard management could reduce mortality and morbidity (death, transplantation/LVAD and rehospitalisation for heart failure) and improve myocardial function at 12 weeks, compared with standard management alone.

03

Conditions studied

  • Cardiogenic Shock

Keywords

  • Heart failure
  • Acute heart failure
  • Cardiogenic shock
  • SGLT2 inhibitor
  • Mortality
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients hospitalized in critical cardiac unit care or Intensive care unit for a cardiogenic shock
  • "Who must have been or is on catecholamines for at least 12 hours for the treatment of cardiogenic shock.
  • Patients who are able to take oral tablets

Exclusion criteria

Exclusion Criteria:

  • \< 20 ml/min/1.73m2.
  • Chronic dialysis.
  • Patient on SGLT2 inhibitors prior to admission to ICU or CCU.
  • Known allergy to SGLT2 inhibitors or to any of its (in particular, patients with hereditary disorders of galactose intolerance, total lactase deficiency or glucose or galactose malabsorption syndrome)
  • Patients on lithium.
  • Patient in shock for another cause or moribund (SAPS2> 90).
  • Specific cardiogenic shock context:

    1. cardiac transplant patient or on transplant list.
    2. peripartum, adrenergic, valvular, non ischemic, post embolic heart disease.
    3. related to cardiotropic drug intoxication.
    4. Secondary to a cardiac arrest for which the patient remains comatose prior to inclusion.
  • Women of childbearing age without effective .
  • Person referred to in Articles 10, 31, 32, 33 and 34 of EU Regulation 536/2014 (Pregnant woman, parturient or breastfeeding mother, Minor (not emancipated), Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice))
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
164 participants (estimated)

Study arms

  • Experimental
    Empaglifozin in addition to standard management

    Patients in cardiogenic shock receiving empagliflozin in addition to standard management at a dose of 10 mg per day per os (or through nasogastric tube in intubated patients) for a duration of 12 weeks

    Drug: Empagliflozin 10 MG

  • No intervention
    Standard management

    Patients in cardiogenic shock receiving a standard management. SGLT2 inhibitor, which are now standard of care in chronic heart failure, in the strict respect of their indications, could be prescribed in the standard management group after hospitalization discharge.

Interventions

  • DrugEmpagliflozinStudies of EmpagliflozinEmpagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients in cardiogenic shock receiving empagliflozin in addition to standard management at a dose of 10 mg per day per os (or through nasogastric tube in intubated patients) for a duration of 12 weeks.

06

What researchers measure

Primary outcomes

  1. Time to all-cause death

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on composite endpoint components: 1. All-cause mortality or heart transplantation or ventricular assist, 2. Rehospitalization for heart failure, 3. Left ventricular ejection fraction. Hierarchical composite endpoint, assessed at 12 weeks from randomization (win-ratio method): * Rank 1: Time to all-cause death or cardiac transplantation or mechanical ventricular assist, * Rank 2: Time to rehospitalization for heart failure, * Rank 3: Left ventricular ejection fraction assessed during a research cardiac ultrasound.

    Time frame: 12-week after randomisation

  2. Time to cardiac transplantation

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on composite endpoint components: 1. All-cause mortality or heart transplantation or ventricular assist, 2. Rehospitalization for heart failure, 3. Left ventricular ejection fraction. Hierarchical composite endpoint, assessed at 12 weeks from randomization (win-ratio method): * Rank 1: Time to all-cause death or cardiac transplantation or mechanical ventricular assist, * Rank 2: Time to rehospitalization for heart failure, * Rank 3: Left ventricular ejection fraction assessed during a research cardiac ultrasound.

    Time frame: 12-week after randomisation

  3. Time to mechanical ventricular assist

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on composite endpoint components: 1. All-cause mortality or heart transplantation or ventricular assist, 2. Rehospitalization for heart failure, 3. Left ventricular ejection fraction. Hierarchical composite endpoint, assessed at 12 weeks from randomization (win-ratio method): * Rank 1: Time to all-cause death or cardiac transplantation or mechanical ventricular assist, * Rank 2: Time to rehospitalization for heart failure, * Rank 3: Left ventricular ejection fraction assessed during a research cardiac ultrasound.

    Time frame: 12-week after randomisation

  4. Time to rehospitalization for heart failure.

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on composite endpoint components: 1. All-cause mortality or heart transplantation or ventricular assist, 2. Rehospitalization for heart failure, 3. Left ventricular ejection fraction. Hierarchical composite endpoint, assessed at 12 weeks from randomization (win-ratio method): * Rank 1: Time to all-cause death or cardiac transplantation or mechanical ventricular assist, * Rank 2: Time to rehospitalization for heart failure, * Rank 3: Left ventricular ejection fraction assessed during a research cardiac ultrasound.

    Time frame: 12-week after randomisation

  5. Left ventricular ejection fraction assessed by cardiac ultrasound.

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on composite endpoint components: 1. All-cause mortality or heart transplantation or ventricular assist, 2. Rehospitalization for heart failure, 3. Left ventricular ejection fraction. Hierarchical composite endpoint, assessed at 12 weeks from randomization (win-ratio method): * Rank 1: Time to all-cause death or cardiac transplantation or mechanical ventricular assist, * Rank 2: Time to rehospitalization for heart failure, * Rank 3: Left ventricular ejection fraction assessed during a research cardiac ultrasound.

    Time frame: 12-week after randomisation

Secondary outcomes

  1. Death

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on all-cause mortality at 12 weeks from randomization

    Time frame: 12-week after randomisation

  2. Heart transplantation or long-term ventricular assistance

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on heart transplantation or long-term ventricular assistance, at 12 weeks from randomization

    Time frame: 12-week after randomisation

  3. Rehospitalization for heart failure

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on rehospitalization for heart failure, at 12 weeks from randomization

    Time frame: from hospital discharge to 12-week after randomisation

  4. Left ventricular ejection fraction assessed by cardiac ultrasound.

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on left ventricular ejection fraction, at 12 weeks from randomization.

    Time frame: 12-week after randomisation

  5. E' wave assessed by cardiac ultrasound

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on the left ventricular diastolic function and filling pressures, at 12 weeks from randomization.

    Time frame: 12-week after randomisation

  6. E/e' ratio assessed by cardiac ultrasound

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on the left ventricular diastolic function and filling pressures, at 12 weeks from randomization.

    Time frame: 12-week after randomisation

  7. TAPSE assessed by cardiac ultrasound

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on the right ventricular function, at 12 weeks from randomization

    Time frame: 12-week after randomisation

  8. S wave at the annular tricuspid level assessed by cardiac ultrasound

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on the right ventricular function, at 12 weeks from randomization

    Time frame: 12-week after randomisation

  9. Renal replacement therapy

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on the renal function, at 12 weeks from randomization

    Time frame: Randomisation and 12-week after randomisation

  10. Renal function

    The number of patients requiring renal replacement therapy between randomization and 12 weeks, and change in renal function assessed at baseline and 12 weeks: glomerular filtration rate calculated by the CKD-EPI method

    Time frame: Randomisation and 12-week after randomisation

  11. Bilirubin

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on the hepatic function, at 12 weeks from randomization

    Time frame: Randomisation and 12-week after randomisation

  12. Prothrombin Ratio (PT)

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on the hepatic function, at 12 weeks from randomization

    Time frame: Randomisation and 12-week after randomisation

  13. SGOT

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on the hepatic function, at 12 weeks from randomization

    Time frame: Randomisation and 12-week after randomisation

  14. SGPT

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on the hepatic function, at 12 weeks from randomization

    Time frame: Randomisation and 12-week after randomisation

  15. NT-Pro-BNP

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on the evolution of the hydro-sodic overload, at 12 weeks from randomization. The measure of NT-Pro-BNP will be measured at 12 weeks and delta from randomisation will be calculated

    Time frame: Randomisation and 12-week after randomisation

  16. Weight

    To compare the effect of early introduction of empagliflozin in addition to standard management versus standard management alone on the evolution of the hydro-sodic overload, at 12 weeks from randomization. The weight will be measured at 12 weeks and delta from randomisation will be calculated

    Time frame: Randomisation and 12-week after randomisation

07

Study locations

5 of 8 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Mar 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
May 30, 2023
StartActual
Dec 16, 2024
Primary completionEst.
Mar 16, 2027
CompletionEst.
Mar 16, 2027
Last update
Jun 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05879276
Responsible party
Dr Antoine KIMMOUN (coordinating investigator, Central Hospital, Nancy, France) — Principal investigator
First posted
May 30, 2023
Start date
Dec 16, 2024
Primary completion
Mar 16, 2027 (estimated)
Completion
Mar 16, 2027 (estimated)
Last update
Jun 27, 2025

Study contacts

Antoine KIMMOUN, MD PhD
Contact
a.kimmoun@chru-nancy.fr
3 83 15 40 79 ext. +33
Dany JANAH, MD
Contact
dany.janah@chu-lille.fr
3 20 44 59 62 ext. +33
Nicolas GIRERD, MD PhD
study chair · CHRU of NANCY

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion